Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Other Working Capital Changes (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Other Working Capital Changes for 10 consecutive years, with $3.9 million as the latest value for Q4 2025.

  • Quarterly Other Working Capital Changes rose 230.31% to $3.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$112000.0 through Dec 2025, up 98.19% year-over-year, with the annual reading at -$112000.0 for FY2025, 98.19% up from the prior year.
  • Other Working Capital Changes for Q4 2025 was $3.9 million at Akebia Therapeutics, up from -$9.5 million in the prior quarter.
  • The five-year high for Other Working Capital Changes was $17.1 million in Q4 2022, with the low at -$10.5 million in Q3 2023.
  • Average Other Working Capital Changes over 5 years is -$780944.4, with a median of -$1.5 million recorded in 2023.
  • The sharpest move saw Other Working Capital Changes skyrocketed 2538.43% in 2022, then plummeted 661.61% in 2025.
  • Over 5 years, Other Working Capital Changes stood at $648000.0 in 2021, then surged by 2538.43% to $17.1 million in 2022, then plummeted by 110.5% to -$1.8 million in 2023, then tumbled by 66.59% to -$3.0 million in 2024, then surged by 230.31% to $3.9 million in 2025.
  • According to Business Quant data, Other Working Capital Changes over the past three periods came in at $3.9 million, -$9.5 million, and $5.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.